Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals EVP Kyle Jenne reported routine equity compensation activity involving restricted stock units and common shares. On April 15, 2026, Jenne exercised 12,226 Restricted Stock Units, each representing a right to receive one share of Ionis common stock pursuant to a prior award.
In connection with this vesting, on April 16, 2026, Jenne completed an automatic sale of 4,902 common shares to cover required tax withholding obligations under the company’s equity incentive plan, at a weighted average price of $75.171 per share, with individual trades ranging from $75.06 to $75.26. Following these transactions, Jenne directly holds 23,713 shares of common stock and 74,402 Restricted Stock Units, which continue to vest in four equal annual installments.
Ionis Pharmaceuticals EVP Brian Birchler reported routine equity compensation activity and a related tax sale. He acquired 1,875 shares of common stock on conversion of Restricted Stock Units that vested under a prior award. The filing notes each RSU converts into one share of Ionis common stock.
To cover required tax withholding obligations from this vesting, 973 common shares were automatically sold at a weighted average price of $75.042 per share, with individual sale prices ranging from $75.01 to $75.06. After these transactions, Birchler directly holds 67,500 common shares, while 48,926 Restricted Stock Units remain outstanding and continue to vest in four equal annual installments.
IONIS PHARMACEUTICALS INC EVP and Chief Business Officer Joseph Baroldi reported RSU vesting and a related tax sale. On April 15, 2026, 10,837 Restricted Stock Units vested and were converted into 10,837 shares of common stock at a conversion price of $0.00 per share.
On April 16, 2026, 5,619 shares of common stock were sold at a weighted average price of $74.56 per share in an automatic sale to cover required tax withholding obligations under the company’s equity incentive plan. Following these transactions, Baroldi directly holds 46,535 common shares and has indirect ownership of 4,347 shares held by his spouse.
Ionis Pharmaceuticals reported Form 144 sales of Common Stock by brokers/dealers on behalf of insiders. The excerpt lists trades with share counts of 4,902, 1,823, and 37,277 executed on 01/16/2026, 03/10/2026, and related RSUs dated 04/15/2026.
Ionis Pharmaceuticals submitted a Form 144 notifying a proposed sale of 973 shares of Common Stock (issued as RSUs under the 2011 Equity Incentive Plan) through Morgan Stanley on 04/16/2026. The filing lists prior share sales in the past three months: 8,480 shares sold on 01/15/2026 for $636,932.80 and 6,179 shares sold on 01/30/2026 for $513,047.87.
Ionis Pharmaceuticals files a Rule 144 notice to sell 5,619 shares of Common Stock. The filing lists the securities as RSUs granted under the 2011 Equity Incentive Plan with an intended sale date of 04/16/2026. The notice also reports prior open-market sales of 4,096, 5,296, and 6,907 shares on 03/03/2026, 01/30/2026, and 01/16/2026, respectively.
Ionis Pharmaceuticals director Joseph Klein III exercised stock options and sold shares on April 1, 2026. He exercised options for 12,000 shares at $38.06 and 10,321 shares at $41.08, acquiring a total of 22,321 common shares. He then sold 20,105 shares at a weighted average price of $75.503 and 2,216 shares at $75.954 in open-market transactions pursuant to a Rule 10b5-1 Trading Plan adopted on November 26, 2025. After these transactions, he held 11,014 shares directly. An additional 100 shares are held indirectly by his son, for which he disclaims beneficial ownership.
Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, sold 6,193 shares of Common Stock in an open-market transaction at a weighted average price of $74.0535 per share on April 2, 2026. The sale was made pursuant to a Rule 10b5-1 Trading Plan adopted on November 24, 2025. After this transaction, Devers directly holds 16,348 shares of Ionis Pharmaceuticals common stock.
IONS notice of proposed sale of 68,800 shares of Common Stock under Rule 144. The form lists a sale venue as Nasdaq and an effective/filing date of 03/03/2026. The excerpt also shows 50,432 shares from an option exercise and 18,368 RSUs with grant dates.
Ionis Pharmaceuticals Inc: The Vanguard Group filed Amendment No. 14 to a Schedule 13G/A reporting beneficial ownership in Ionis Pharmaceuticals common stock. The filing states 0 shares beneficially owned and 0% of the class, after an internal realignment of Vanguard subsidiaries.
The filing explains that on January 12, 2026 Vanguard reorganized certain subsidiaries to report separately in reliance on SEC Release No. 34-39538; the reporting entity now states no beneficial ownership in the class. The form is signed by Ashley Grim, Head of Global Fund Administration.